Veracyte will present seven abstracts showcasing its genomic tests for prostate and breast cancers at the European Society for Medical Oncology (ESMO) Congress 2022.
The following abstracts will be shared at the event in Paris on September 11:
- Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial
- A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer
- Transcriptomic based indicators of potential therapeutic response to target therapy among 50,000 men with localized prostate cancer
- Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 Randomized Phase III Trials
- Transcriptomic-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)
- Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa)
- Current use of breast cancer multigene signatures in clinical practice among European experts: Results from the PROCURE Project
